Table 1.
Change in hemodynamic parameters: response to L-NMMA during study periods
| Variable | Baseline visit | Change postplacebo | Change postallopurinol | Difference between periods* | P |
|---|---|---|---|---|---|
| ICA flow (ml)† | −789 (−4,194 to 735) | −1,314 (−3,359 to 419) | 1,134 (−964 to 7,872) | 3,144 (375 to 7,143) | 0.032 |
| Systolic blood pressure (mmHg)† | −133 (−205 to 94) | 20 (−260 to 158) | 116 (−248 to 501) | 14 (−461 to 588) | 0.919 |
| Diastolic blood pressure (mmHg)† | 66 (−60 to 276) | −55 (−220 to 86) | −162 (−206 to 94) | −56 (−218 to 90) | 0.476 |
| Middle cerebral artery flow velocity (ml/s)† | 14 (−29 to 53) | −41 (−112 to 108) | −38 (−146 to −9) | −35 (−174 to 45) | 0.359 |
| Augmentation index (%)‡ | 23.5 (18.5–29.5) | −3 (−14.5 to 4.5) | 2 (−6.00 to 10) | −4.3 (−11 to 7) | 0.56 |
| PWV (m/s)‡ | 9 (7.6–9.6) | 0.8 (0.1–10.2) | 0.75 (−0.85 to 2.3) | −0.32 (−2.1 to 7.8) | 0.39 |
| Vascular endothelial growth factor (pg/ml)‡ | 90.4 (42.9–226.3) | −14 (−67 to 59.1) | 66.9 (5.9–119.6) | 91 (−53 to 151) | 0.083 |
| Soluble intercellular adhesion molecules (ng/ml)‡ | 414 (336–555.8) | 73.6 (−85.3 to 96.5) | 9 (−7.8 to 65.3) | −51.7 (−81 to 91.9) | 0.689 |
| E-selectin (ng/ml)‡ | 85.1 (63.8–116.3) | 0.01 (−14.6 to 10.3) | 2.4 (−12.9 to 17.1) | 16 (−19 to 26) | 0.45 |
| C-reactive proteins (mg/l)‡ | 1.02 (0.5–1.1) | 0.09 (−0.3 to 0.75) | 0.195 (−0.01 to 1) | 0.33 (−0.48 to 1.29) | 0.398 |
Data are median (interquartile range) unless otherwise indicated.
*
Data are estimated differences in medians (95% CI) by Wilcoxon's signed-rank test.
†
Data refer to the change in area under the time curve in response to L-NMMA.
‡
Data refer to the difference between preinfusion values. P values were determined by Wilcoxon's signed-rank test.